iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Hallek, Michael, Cheson, Bruce D., Catovsky, Daniel, Caligaris-Cappio, Federico, Dighiero, Guillermo, Döhner, Hartmut, Hillmen, Peter, Keating, Michael, Montserrat, Emili, Chiorazzi, Nicholas, Stilgenbauer, Stephan, Rai, Kanti R., Byrd, John C., Eichhorst, Barbara, O'Brien, Susan, Robak, Tadeusz, Seymour, John F., Kipps, Thomas J.
Published in Blood (21.06.2018)
Published in Blood (21.06.2018)
Get full text
Journal Article
Hypertension and incident cardiovascular events following ibrutinib initiation
Dickerson, Tyler, Wiczer, Tracy, Waller, Allyson, Philippon, Jennifer, Porter, Kyle, Haddad, Devin, Guha, Avirup, Rogers, Kerry A., Bhat, Seema, Byrd, John C., Woyach, Jennifer A., Awan, Farrukh, Addison, Daniel
Published in Blood (28.11.2019)
Published in Blood (28.11.2019)
Get full text
Journal Article
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
Sharman, Jeff P, Egyed, Miklos, Jurczak, Wojciech, Skarbnik, Alan, Pagel, John M, Flinn, Ian W, Kamdar, Manali, Munir, Talha, Walewska, Renata, Corbett, Gillian, Fogliatto, Laura Maria, Herishanu, Yair, Banerji, Versha, Coutre, Steven, Follows, George, Walker, Patricia, Karlsson, Karin, Ghia, Paolo, Janssens, Ann, Cymbalista, Florence, Woyach, Jennifer A, Ferrant, Emmanuelle, Wierda, William G, Munugalavadla, Veerendra, Yu, Ting, Wang, Min Hui, Byrd, John C
Published in Leukemia (01.04.2022)
Published in Leukemia (01.04.2022)
Get full text
Journal Article
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
Byrd, John C, Hillmen, Peter, Ghia, Paolo, Kater, Arnon P, Chanan-Khan, Asher, Furman, Richard R, O'Brien, Susan, Yenerel, Mustafa Nuri, Illés, Arpad, Kay, Neil, Garcia-Marco, Jose A, Mato, Anthony, Pinilla-Ibarz, Javier, Seymour, John F, Lepretre, Stephane, Stilgenbauer, Stephan, Robak, Tadeusz, Rothbaum, Wayne, Izumi, Raquel, Hamdy, Ahmed, Patel, Priti, Higgins, Kara, Sohoni, Sophia, Jurczak, Wojciech
Published in Journal of clinical oncology (01.11.2021)
Published in Journal of clinical oncology (01.11.2021)
Get full text
Journal Article
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
Buhimschi, Alexandru D, Armstrong, Haley A, Toure, Momar, Jaime-Figueroa, Saul, Chen, Timothy L, Lehman, Amy M, Woyach, Jennifer A, Johnson, Amy J, Byrd, John C, Crews, Craig M
Published in Biochemistry (Easton) (03.07.2018)
Published in Biochemistry (Easton) (03.07.2018)
Get full text
Journal Article
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
Brown, Jennifer R, Moslehi, Javid, O'Brien, Susan, Ghia, Paolo, Hillmen, Peter, Cymbalista, Florence, Shanafelt, Tait D, Fraser, Graeme, Rule, Simon, Kipps, Thomas J, Coutre, Steven, Dilhuydy, Marie-Sarah, Cramer, Paula, Tedeschi, Alessandra, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C, Howes, Angela, Todd, Michael, Vermeulen, Jessica, James, Danelle F, Clow, Fong, Styles, Lori, Valentino, Rudy, Wildgust, Mark, Mahler, Michelle, Burger, Jan A
Published in Haematologica (Roma) (01.10.2017)
Published in Haematologica (Roma) (01.10.2017)
Get full text
Journal Article
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
O'Brien, Susan, Furman, Richard R., Coutre, Steven, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Wierda, William, Jones, Jeffrey, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Luan, Ying, James, Danelle F., Chu, Alvina D., Byrd, John C.
Published in Blood (26.04.2018)
Published in Blood (26.04.2018)
Get full text
Journal Article
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
Turtle, Cameron J, Hay, Kevin A, Hanafi, Laïla-Aïcha, Li, Daniel, Cherian, Sindhu, Chen, Xueyan, Wood, Brent, Lozanski, Arletta, Byrd, John C, Heimfeld, Shelly, Riddell, Stanley R, Maloney, David G
Published in Journal of clinical oncology (10.09.2017)
Published in Journal of clinical oncology (10.09.2017)
Get full text
Journal Article
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Roberts, Andrew W., Ma, Shuo, Kipps, Thomas J., Coutre, Steven E., Davids, Matthew S., Eichhorst, Barbara, Hallek, Michael, Byrd, John C., Humphrey, Kathryn, Zhou, Lang, Chyla, Brenda, Nielsen, Jacqueline, Potluri, Jalaja, Kim, Su Young, Verdugo, Maria, Stilgenbauer, Stephan, Wierda, William G., Seymour, John F.
Published in Blood (11.07.2019)
Published in Blood (11.07.2019)
Get full text
Journal Article
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, John C, Harrington, Bonnie, O’Brien, Susan, Jones, Jeffrey A, Schuh, Anna, Devereux, Steve, Chaves, Jorge, Wierda, William G, Awan, Farrukh T, Brown, Jennifer R, Hillmen, Peter, Stephens, Deborah M, Ghia, Paolo, Barrientos, Jacqueline C, Pagel, John M, Woyach, Jennifer, Johnson, Dave, Huang, Jane, Wang, Xiaolin, Kaptein, Allard, Lannutti, Brian J, Covey, Todd, Fardis, Maria, McGreivy, Jesse, Hamdy, Ahmed, Rothbaum, Wayne, Izumi, Raquel, Diacovo, Thomas G, Johnson, Amy J, Furman, Richard R
Published in The New England journal of medicine (28.01.2016)
Published in The New England journal of medicine (28.01.2016)
Get full text
Journal Article
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial
Sharman, Jeff P, Egyed, Miklos, Jurczak, Wojciech, Skarbnik, Alan, Pagel, John M, Flinn, Ian W, Kamdar, Manali, Munir, Talha, Walewska, Renata, Corbett, Gillian, Fogliatto, Laura Maria, Herishanu, Yair, Banerji, Versha, Coutre, Steven, Follows, George, Walker, Patricia, Karlsson, Karin, Ghia, Paolo, Janssens, Ann, Cymbalista, Florence, Woyach, Jennifer A, Salles, Gilles, Wierda, William G, Izumi, Raquel, Munugalavadla, Veerendra, Patel, Priti, Wang, Min Hui, Wong, Sofia, Byrd, John C
Published in The Lancet (British edition) (18.04.2020)
Published in The Lancet (British edition) (18.04.2020)
Get full text
Journal Article
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
Byrd, John C., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Tam, Constantine S., Mulligan, Stephen P., Jaeger, Ulrich, Barr, Paul M., Furman, Richard R., Kipps, Thomas J., Thornton, Patrick, Moreno, Carol, Montillo, Marco, Pagel, John M., Burger, Jan A., Woyach, Jennifer A., Dai, Sandra, Vezan, Remus, James, Danelle F., Brown, Jennifer R.
Published in Blood (09.05.2019)
Published in Blood (09.05.2019)
Get full text
Journal Article
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Byrd, John C, Furman, Richard R, Coutre, Steven E, Flinn, Ian W, Burger, Jan A, Blum, Kristie, Sharman, Jeff P, Wierda, William, Zhao, Weiqiang, Heerema, Nyla A, Luan, Ying, Liu, Emily A, Dean, James P, O'Brien, Susan
Published in Clinical cancer research (01.08.2020)
Published in Clinical cancer research (01.08.2020)
Get full text
Journal Article